| Name | Title | Contact Details |
|---|
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
Biorasi is an award-winning full service, global Clinical Research Optimized (CRO). From project design to execution success, optimization is engrained in ProAct+. An integrated platform of high performance systems, tools, and processes. By developing and implementing groundbreaking methods of optimizing clinical research, we contribute to enhancement of health and well-being for people around the world. Powered by ProAct+, Biorasi`s full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional operations around the world.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
SK Life Sciences is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.